RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Metabolon, Inc., the leader in metabolomics-driven biomarker discovery and analysis, announced today the implementation of its metabolomics technology at Pfizer’s Bioprocess R&D Group. This global biochemical profiling technology, called mVision, will provide analysis of samples from bioreactors. Using mVision, Pfizer will be able to rapidly understand cellular metabolism in the biopharmaceutical production process, which in turn will enable Pfizer to optimize bioprocesses and to reduce manufacture costs.
